Compassionate Use

FDA just simplified the “compassionate use” process. But what does this mean for the life sciences industry?

The FDA is simplifying its compassionate use process, aiming to make it easier for terminally ill patients to access potentially life-saving drugs, reports Alexander Gaffney over at RAPS. This could have some rather interesting implications for the life sciences industry – companies and regulators alike, Gaffney said, are actually concerned by this change in plans. It could […]